PLYMOUTH, Mass.--(BUSINESS WIRE)--Harvest Technologies Corp. (www.harvesttech.com) announced today that Claas Lüdermann, MD, a specialist in vascular medicine, presented preliminary data at the 74th Annual Meeting of the German Society of Cardiology from a clinical trial being conducted at the Berlin (Germany) Vascular Center of Franziskus Hospital under the direction of Berthold Amman, MD. The “BONe Marrow Outcome Trial-2” (BONMOT-2) is a randomized, controlled, double-blinded study treating patients with end-stage peripheral vascular disease (Critical Limb Ischemia, or CLI), using a cellular composition of autologous stem cells. This same treatment methodology has shown to be very promising in international clinical pilot studies, including a successful pilot study (BONMOT-1) of 60 patients recently completed under Dr. Amann’s supervision at the Berlin Vascular Center.
